Xconomy New York — Perceptive Advisors, an investment firm with a long track record of life science investing across all points of development, is now stepping up to pump money into companies at the earliest stages with a new $210 million venture capital fund.
The Perceptive Xontogeny Venture Fund (PXV) is led by Chris Garabedian (pictured above, center), a veteran biotech executive whose experience includes stops at Gilead Sciences (NASDAQ: GILD), Celgene, and Sarepta Therapeutics (NASDAQ: SRPT). He’s currently the chairman and CEO of Xontogeny, a Boston-based life sciences accelerator.
Image: https://xconomy.com
{iframe}https://xconomy.com/new-york/2019/12/10/perceptive-unveils-new-200m-fund-to-invest-in-early-stage-biotechs/{/iframe}